Literature DB >> 29235861

KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.

Jia Lu1, Asim K Bera1, Sudershan Gondi1, Kenneth D Westover1.   

Abstract

KRAS switch loop movements play a crucial role in regulating RAS signaling, and alteration of these sensitive dynamics is a principal mechanism through which disease-associated RAS mutations lead to aberrant RAS activation. Prior studies suggest that despite a high degree of sequence similarity, the switches in KRAS are more dynamic than those in HRAS. We determined X-ray crystal structures of the rare tumorigenic KRAS mutants KRASD33E, in switch 1 (SW1), and KRASA59G, in switch 2 (SW2), bound to GDP and found these adopt nearly identical, open SW1 conformations as well as altered SW2 conformations. KRASA59G bound to a GTP analogue crystallizes in the same conformation. This open conformation is consistent with the inactive "state 1" previously observed for HRAS bound to GTP. For KRASA59G, switch rearrangements may be regulated by increased flexibility in the 57DXXGQ61 motif at codon 59. However, loss of interactions between side chains at codons 33 and 35 in the SW1 33DPT35 motif drives changes for KRASD33E. The 33DPT35 motif is conserved for multiple members of the RAS subfamily but is not found in RAB, RHO, ARF, or Gα families, suggesting that dynamics mediated by this motif may be important for determining the selectivity of RAS-effector interactions. Biochemically, the consequence of altered switch dynamics is the same, showing impaired interaction with the guanine exchange factor SOS and loss of GAP-dependent GTPase activity. However, interactions with the RBD of RAF are preserved. Overall, these observations add to a body of evidence suggesting that HRAS and KRAS show meaningful differences in functionality stemming from differential protein dynamics independent of the hypervariable region.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29235861      PMCID: PMC8691853          DOI: 10.1021/acs.biochem.7b00974

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  51 in total

1.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Authors:  Matthew P Patricelli; Matthew R Janes; Lian-Sheng Li; Rasmus Hansen; Ulf Peters; Linda V Kessler; Yuching Chen; Jeff M Kucharski; Jun Feng; Tess Ely; Jeffrey H Chen; Sarah J Firdaus; Anjali Babbar; Pingda Ren; Yi Liu
Journal:  Cancer Discov       Date:  2016-01-06       Impact factor: 39.397

2.  Structure of the G60A mutant of Ras: implications for the dominant negative effect.

Authors:  Bradley Ford; Karlheinz Skowronek; Sean Boykevisch; Dafna Bar-Sagi; Nicolas Nassar
Journal:  J Biol Chem       Date:  2005-05-05       Impact factor: 5.157

3.  Purine nucleoside phosphorylase: its use in a spectroscopic assay for inorganic phosphate and for removing inorganic phosphate with the aid of phosphodeoxyribomutase.

Authors:  A E Nixon; J L Hunter; G Bonifacio; J F Eccleston; M R Webb
Journal:  Anal Biochem       Date:  1998-12-15       Impact factor: 3.365

4.  Processing of X-ray diffraction data collected in oscillation mode.

Authors:  Z Otwinowski; W Minor
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

5.  Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD.

Authors:  Susan K Fetics; Hugo Guterres; Bradley M Kearney; Greg Buhrman; Buyong Ma; Ruth Nussinov; Carla Mattos
Journal:  Structure       Date:  2015-02-12       Impact factor: 5.006

6.  Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.

Authors:  Mei Zeng; Jia Lu; Lianbo Li; Frederic Feru; Chunshan Quan; Thomas W Gero; Scott B Ficarro; Yuan Xiong; Chiara Ambrogio; Raymond M Paranal; Marco Catalano; Jay Shao; Kwok-Kin Wong; Jarrod A Marto; Eric S Fischer; Pasi A Jänne; David A Scott; Kenneth D Westover; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2017-08-03       Impact factor: 8.116

Review 7.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

8.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.

Authors:  Piro Lito; Martha Solomon; Lian-Sheng Li; Rasmus Hansen; Neal Rosen
Journal:  Science       Date:  2016-01-14       Impact factor: 47.728

9.  Mutations of Ha-ras p21 that define important regions for the molecular mechanism of the SDC25 C-domain, a guanine nucleotide dissociation stimulator.

Authors:  M Y Mistou; E Jacquet; P Poullet; H Rensland; P Gideon; I Schlichting; A Wittinghofer; A Parmeggiani
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

10.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.

Authors:  S Bamford; E Dawson; S Forbes; J Clements; R Pettett; A Dogan; A Flanagan; J Teague; P A Futreal; M R Stratton; R Wooster
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  14 in total

1.  Structural basis of the atypical activation mechanism of KRASV14I.

Authors:  Asim K Bera; Jia Lu; Thomas E Wales; Sudershan Gondi; Deepak Gurbani; Andrew Nelson; John R Engen; Kenneth D Westover
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

2.  Regulation of GTPase function by autophosphorylation.

Authors:  Christian W Johnson; Hyuk-Soo Seo; Elizabeth M Terrell; Moon-Hee Yang; Fenneke KleinJan; Teklab Gebregiworgis; Genevieve M C Gasmi-Seabrook; Ezekiel A Geffken; Jimit Lakhani; Kijun Song; Puspalata Bashyal; Olesja Popow; Joao A Paulo; Andrea Liu; Carla Mattos; Christopher B Marshall; Mitsuhiko Ikura; Deborah K Morrison; Sirano Dhe-Paganon; Kevin M Haigis
Journal:  Mol Cell       Date:  2022-02-23       Impact factor: 17.970

3.  Delineating the RAS Conformational Landscape.

Authors:  Mitchell I Parker; Joshua E Meyer; Erica A Golemis; Roland L Dunbrack
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

4.  GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R.

Authors:  Asim K Bera; Jia Lu; Chunya Lu; Lianbo Li; Sudershan Gondi; Wei Yan; Andrew Nelson; Goujun Zhang; Kenneth D Westover
Journal:  Birth Defects Res       Date:  2020-03-18       Impact factor: 2.344

5.  The to and fro of Rho.

Authors:  Kenneth D Westover
Journal:  Structure       Date:  2021-06-03       Impact factor: 5.006

6.  Structure of an inactive conformation of GTP-bound RhoA GTPase.

Authors:  Yuan Lin; Shaoyong Lu; Jian Zhang; Yi Zheng
Journal:  Structure       Date:  2021-01-25       Impact factor: 5.871

7.  Drugging multiple same-allele driver mutations in cancer.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Hyunbum Jang
Journal:  Expert Opin Drug Discov       Date:  2021-03-26       Impact factor: 7.050

8.  Massively parallel phenotyping of coding variants in cancer with Perturb-seq.

Authors:  Oana Ursu; James T Neal; Emily Shea; Pratiksha I Thakore; Livnat Jerby-Arnon; Lan Nguyen; Danielle Dionne; Celeste Diaz; Julia Bauman; Mariam Mounir Mosaad; Christian Fagre; April Lo; Maria McSharry; Andrew O Giacomelli; Seav Huong Ly; Orit Rozenblatt-Rosen; William C Hahn; Andrew J Aguirre; Alice H Berger; Aviv Regev; Jesse S Boehm
Journal:  Nat Biotechnol       Date:  2022-01-20       Impact factor: 68.164

9.  Structures of N-terminally processed KRAS provide insight into the role of N-acetylation.

Authors:  Srisathiyanarayanan Dharmaiah; Timothy H Tran; Simon Messing; Constance Agamasu; William K Gillette; Wupeng Yan; Timothy Waybright; Patrick Alexander; Dominic Esposito; Dwight V Nissley; Frank McCormick; Andrew G Stephen; Dhirendra K Simanshu
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

10.  Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer.

Authors:  Jiaxin Zhang; Zuojia Liu; Wenjing Zhao; Xunzhe Yin; Xiliang Zheng; Chuanbo Liu; Jin Wang; Erkang Wang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.